Royal Bank of Canada Has $109,000 Stake in MiMedx Group, Inc $MDXG

Royal Bank of Canada reduced its stake in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 87.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,468 shares of the company’s stock after selling 186,366 shares during the quarter. Royal Bank of Canada’s holdings in MiMedx Group were worth $109,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Kemnay Advisory Services Inc. acquired a new stake in shares of MiMedx Group in the 4th quarter valued at $48,000. Jain Global LLC bought a new position in MiMedx Group during the 4th quarter valued at about $73,000. Virtu Financial LLC acquired a new position in MiMedx Group in the fourth quarter valued at about $78,000. Headlands Technologies LLC acquired a new position in MiMedx Group in the second quarter valued at about $72,000. Finally, Cresset Asset Management LLC bought a new stake in MiMedx Group during the third quarter worth about $86,000. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on MDXG shares. Weiss Ratings upgraded shares of MiMedx Group from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price target on shares of MiMedx Group in a research report on Monday, August 17th. Wall Street Zen raised MiMedx Group from a “sell” rating to a “hold” rating in a report on Saturday. Seaport Research Partners downgraded MiMedx Group to a “neutral” rating in a research report on Monday, August 17th. Finally, Raymond James Financial set a $8.00 price objective on MiMedx Group in a research report on Monday, August 17th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.57.

MiMedx Group Stock Performance

MDXG stock opened at $4.54 on Tuesday. The company has a 50 day moving average price of $4.20 and a 200 day moving average price of $4.08. MiMedx Group, Inc has a fifty-two week low of $3.03 and a fifty-two week high of $7.97. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. The stock has a market capitalization of $661.75 million, a PE ratio of 113.53 and a beta of 1.45.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). The firm had revenue of $64.36 million for the quarter, compared to analyst estimates of $63.46 million. MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%. Analysts forecast that MiMedx Group, Inc will post -0.1 EPS for the current year.

MiMedx Group Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.